RT Journal Article
T1 Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth.
A1 Kamposioras, Konstantinos
A1 Mauri, Davide
A1 Papadimitriou, Konstantinos
A1 Anthoney, Alan
A1 Hindi, Nadia
A1 Petricevic, Branka
A1 Dambrosio, Mario
A1 Valachis, Antonis
A1 Kountourakis, Pantelis
A1 Kopecky, Jindrich
A1 Kuhar, Cvetka Grašič
A1 Popovic, Lazar
A1 Chilingirova, Nataliya P
A1 Zarkavelis, George
A1 de Mello, Ramon Andrade
A1 Plavetić, Natalija Dedić
A1 Christopoulos, Christos
A1 Mostert, Bianca
A1 Goffin, John R
A1 Tzachanis, Dimitiros
A1 Saraireh, Haytham Hamed
A1 Ma, Fei
A1 Pavese, Ida
A1 Tolia, Maria
K1 Covid-19
K1 international
K1 oncology
K1 recommendations
K1 societies
AB Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
SN 2234-943X
YR 2020
FD 2020-11-19
LK https://hdl.handle.net/10668/27390
UL https://hdl.handle.net/10668/27390
LA en
DS RISalud
RD Apr 10, 2025